TransCode
RNAZ
TransCode (RNAZ) news
Recent news
Transcode Therapeutics - Three patients remain progression-free at one year
TransCode Therapeutics, Inc. (NASDAQ: TCDT) has reported that three patients treated with its lead therapeutic candidate, TTX-MC138, remain progression-free at one year. This update comes as the company continues to advance its clinical development programs in oncology. TTX-MC138 is an…
AInvest Wire · Sep 28, 2026Transcode Therapeutics - Primary endpoint of phase 1A study met
AInvest Wire · Sep 28, 2026Transcode reports continued disease stabilization and extended treatment duration with TTX-MC138 in ongoing phase 1A clinical trial follow-up
AInvest Wire · Sep 28, 2026Transcode Therapeutics - Announces patent advancements in Australia and Japan for RNA platform
AInvest Wire · Sep 22, 2026Transcode names John Tattory interim CFO
AInvest Wire · Sep 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.